The Next Hot Sector is Upon us and You Will Never Guess What It is

New York, NY -- April 16, 2020 -- InvestorsHub NewsWire -- via Traders News Source -- Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies’ issues their latest research “The Next Hot Sector”

SCWorx Corp. (NASDAQ: WORX) has received a committed purchase order from Rethink My Healthcare, a U.S.-based virtual healthcare network, for 2 million coronavirus testing kits. SCWorx will supply Rethink My Healthcare with IgM/IgG Rapid Detection Kits. SCWorx said it expects to receive the first 2 million rapid detection kits within approximately two weeks. The company said the agreement includes a “provision" for additional weekly orders of 2 million units for 23 weeks, valued at $35 million per week. The IgM/IgG Rapid Test is an in-vitro diagnostic test solely for the qualitative determination of Covid-19’s IgM and IgG antibodies in human whole blood, serum, plasma and fingertip blood. The company also stated that additional purchase orders currently under negotiation with certain other parties could further increase the U.S. supply of these important tests in the near term.

On April 14th, Premier Biomedical Inc. (OTC: BIEI) announced the filing of a provisional patent application, "Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients," The provisional patent application involves the targeted removal of disease-specific antigens via an extracorporeal process. These antigens have been identified in the medical literature to be the pathophysiologic basis for the overwhelming production of lung edema and mucus in Covid-19 patients. The core of this technology is the selective removal of blood-borne antigens associated with the ability of Covid-19 to replicate and is consistent with their patented core technology. The company states it has proven in the laboratory that they can remove specific selected blood-borne antigens from a similar mixture using their patented technology.

Ever wish you were aware of a hot new sector before it experiences explosive growth? Hot new sector in its infancy gaining traction now READ MORE
Copy and paste to browser may be required https://www.industrynews.tips/

Predictive Technology Group, Inc. (OTC: PRED) harnesses predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics. The company is involved in a collaboration with Atrin Pharmaceuticals to utilize next-generation genomics capabilities to improve predictive selection of clinical study patients most likely to respond and least likely to experience side effects from treatment with Atrin’s DDR drug candidates. Atrin and Predictive have been jointly developing proprietary approaches to better identify patients with specific mutations that drive cancer tumor growth, regardless of tumor type, and who are most likely to clinically respond to synthetically lethal anti-cancer therapies.

CytoDyn Inc. (OTCQB: CYDY) reported recently it had filed an Investigational New Drug (IND) application to launch a Phase 2 trial in the U.S. with leronlimab (PRO 140) in patients infected with the COVID-19 coronavirus. Deaths caused by COVID-19 are mostly a result of acute respiratory distress syndrome (ARDS), as the virus in human lungs causes an influx of macrophage and immune cells and the cytokines released result in even more influx of immune cells and inflammation. As an immunomodulator, leronlimab could disrupt this cycle and reduce ARDS-related mortality.

Ever wish you were aware of a hot new sector before it experiences explosive growth? Hot new sector in its infancy gaining traction now READ MORE
Copy and paste to browser may be required –  https://www.industrynews.tips/




Disclosure
 
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
 
 
PRESS RELEASE PROCEDURES
 
The sponsored and non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
 
NO WARRANTY
 
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
 
NOT AN OFFERING
 
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To read our report(s), disclosures, or for more information, visit http://www.tradersnewssource.com.
 
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com
 
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source

Premier Biomedical (PK) (USOTC:BIEI)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

Premier Biomedical (PK) (USOTC:BIEI)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024